Key result
Xuesaitong attenuated albuminuria, mesangial expansion, and podocyte apoptosis in diabetic rats, partly through modulating the PTEN-PDK1-Akt-mTOR pathway.
Why the study?
Diabetic kidney disease is a major cause of ESRD with limited progression-delaying strategies, and identifying novel therapeutic options targeting early podocyte apoptosis is needed.
Does Xuesaitong reduce podocyte apoptosis and albuminuria in streptozotocin-induced diabetic rats?
Population
Streptozotocin-induced diabetic rats
Comparison
XST (5 mg/kg·d) vs Losartan (10 mg/kg·d)
Design
Animal experimental study
Follow-up
12 weeks
Authors
Loading...
Hypothesis-generating for renoprotection in diabetic models; leaves open translation to human diabetic kidney disease.
Does Xuesaitong reduce podocyte apoptosis and albuminuria in streptozotocin-induced diabetic rats?
Xuesaitong protects against diabetic kidney disease progression in a rat model by reducing podocyte apoptosis via the PTEN-PDK1-Akt-mTOR pathway.
Xue et al. (2020) studied Diabetic kidney disease. Xuesaitong (XST) vs. Losartan (10 mg/kg·d) or untreated diabetic rats was evaluated on Podocyte apoptosis, albuminuria, and renal histopathology. Xuesaitong attenuated albuminuria, mesangial expansion, and podocyte apoptosis in diabetic rats, partly through modulating the PTEN-PDK1-Akt-mTOR pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: